Efficacy outcomes in first-line (1L) non–small cell lung cancer (NSCLC) with maintenance of immune competence: QUILT‑2.023 randomized phase 3 study of IL‑15R agonist nogapendekin alfa inbakicept (NAI) with checkpoint inhibitor (CPI) ± chemotherapy.
Response in first-in-human chemotherapy-free combination immunotherapy targeting lymphopenia in recurrent glioblastoma multiform (GBM): Nogapendekin alfa inbakicept (NAI) and PD-L1 t-haNK plus bevacizumab (BEV).
Phase 3 trial ResQ201A of nogapendekin alfa inbakicept (NAI) plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy.

Final full text available 5/21

https://www.asco.org/annual-meeting/search?contentKey=ANNUAL_MEETING&contentKeyYear=2026&userInput=Patrick%20soon%20shiong

reddit.com

u/Professional_Panic67 — 4 months ago

▲ 24 r/IBRX

This is an open-label, randomized, phase 3 study of intravesical BCG plus ANKTIVA (experimental arm) versus BCG alone (control arm) in participants who have histologically confirmed, BCG-naïve/BCG-exposed high-grade Ta/T1 papillary disease. The purpose of this study is to evaluate the contribution of effect of neoadjuvant ANKTIVA plus BCG experimental therapy in papillary NMIBC.

https://clinicaltrials.gov/study/NCT07551544?term=Immunitybio&viewType=Table&sort=StudyFirstPostDate&limit=100&page=1&rank=1

reddit.com

u/Professional_Panic67 — 4 months ago

u/Professional_Panic67

Going to be a busy fall...

New Oropharyngeal Trial

Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now

June shaping up for the next move back to 8+

HC Wainwright &amp; Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target